Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Diode laser in treating secondary neovascular glaucoma

Poster Details

First Author: A. Egorov RUSSIAN FEDERATION

Co Author(s):    F. Nikolay   K. Dmitrii                 

Abstract Details


Evaluation of efficiency of diode laser in treating secondary neovascular glaucoma.


City Clinical Hospital No 15 na OM Filatov, Moscow


The study involved 18 patients (18 eyes), including men and women aged 51 to 64 years old, who had had occlusion of the central retinal vein and diagnosed with stage 2 neovascular glaucoma (NVG) (level of intraocular pressure (IOP) ranging from 27 to 35 mm hg, visualization of neovasculature detected with the use ofslit-lamp and gonioscopy lens). The patients were subjected to the sectoral modified diode cyclo coagulation with the ophtalmosurgical diode laser ALOD-01-'ALKOM' using infra-red rays.


The study showed that during the early postoperative period (5 days after the operation) the quantity of neovasculature was smaller and the IOP's level was 3-5 mm hg lower. A month after the sectoral modified diode cyclocoagulation there was no neovasculature detected by the slit-lamp and gonioscopy, the IOP's level was 7-10 mm hg lower. After the operation the patients were prescribed to take sol. Nepafenaci 0,1% (1 drop three times a day) during 4 weeks.In the course of observation in postoperative period the first day after the operation in 2 cases there was a conjunctive irritation that was corrected in 3 days due to the anti-inflammatory therapy (sol. Nepafenaci 0,1%, 1 drop three times a day).


The study showed that the use of the diode laser in treating secondary neovascular glaucoma is a perspective method that corrects the problem of neovasculature at minimum risk of development of complications during the postoperative period.

Financial Disclosure:


Back to Poster listing